黄芪颗粒联合氢化可的松琥珀酸钠治疗过敏性紫癜临床疗效与安全性探究  

Clinical Efficacy and safety of Huangqi Granule(黄芪颗粒)Combined with Sodium Hydrocortisone Succinate in Treatment of Allergic Purpura

作　　者：王士杰[1] 胡方起 和平 余必信[1] 邓芳[2] WANG Shijie;HU Fangqi;HE Ping;YU Bixin;DENG Fang(Anqing Municipal Hospital,Anqing 246000,Anhui,China;Provincial Childrens Hospital Affiliated to Anhui Medical University,Hefei 230000,Anhui,China)

机构地区：[1]安庆市立医院,安徽安庆246000 [2]安徽医科大学附属省儿童医院,安徽合肥230000

出　　处：《中华中医药学刊》2021年第9期169-172,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：安徽省重点研究与开发计划(202004j07020028)。

摘　　要：目的探究黄芪颗粒联合氢化可的松琥珀酸钠治疗过敏性紫癜临床疗效与安全性。方法研究纳入97例过敏性紫癜患者,均由医院儿科2018年2月—2020年2月收治,采取随机数字表法将纳入患者分为对照组与观察组,予以对照组患者(48例)氢化可的松琥珀酸钠治疗,予以观察组患者(49例)黄芪颗粒联合氢化可的松琥珀酸钠治疗,比较两组患者治疗效果、皮肤紫癜、关节症状、胃肠道症状及住院时间、C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)、白介素6(IL-6)、白介素8(IL-8)水平变化、胱抑素C变化及免疫球蛋白A(IgA)及免疫球蛋白M(IgM)、患者治疗不良反应及6个月后复发率。结果观察组患者治疗总有效率(91.84%,45/49)高于对照组(75.00%,36/48),P<0.05;观察组患者皮肤紫癜、关节症状、胃肠道症状及肾损伤症状缓解时间、住院时间均短于对照组,P<0.01;治疗前,两组患者CRP、TNF-α、IL-6、IL-8水平及胱抑素C、IgA、IgM水平等指标比较,P>0.05,治疗后各组患者CRP、TNF-α、IL-6、IL-8水平及胱抑素C、IgA及IgM水平等指标均改善,观察组患者治疗后CRP、TNF-α、IL-6、IL-8水平、胱抑素C、IgA及IgM水平等指标均优于对照组(P<0.05);观察组出现1例乏力(2.04%),对照组出现1例头痛(2.08%),P>0.05;观察组6个月复发率4例(8.16%)低于对照组11例(22.92%)(P<0.05)。结论黄芪颗粒联合氢化可的松琥珀酸钠治疗过敏性紫癜临床疗效佳,患者症状改善,恢复快,且患者血清炎症因子水平降低,不良反应率低,复发率低,安全性高,值得应用。Objective To explore the clinical efficacy and safety of Huangqi Granule(黄芪颗粒) combined with sodium hydrocortisone succinate in the treatment of allergic purpura. Methods A total of 97 patients with allergic purpura in our hospital from February 2018 to February 2020 were analyzed. According to the random number table method, the patients were divided into control group and observation group. The control group(48 cases) were treated with hydrocortisone sodium succinate. The observation group(49 cases) were treated with Huangqi Granule and hydrocortisone sodium succinate. The treatment effect, skin purpura, joint symptoms, gastrointestinal symptoms and hospitalization time, C-reactive protein(CRP) and tumor necrosis factor-α(TNF-α),the changes of IL-6, IL-8, cystatin C, IgA and IgM, the adverse reactions and the recurrence rate after 6 months were compared between the two groups. Results The total effective rate(91.84%,45/49) in the observation group was higher than that in the control group(75.00%,36/48)(P<0.05). In the observation group, the remission time and hospital stay time of skin purpura, joint symptoms, gastrointestinal symptoms and renal injury symptoms were shorter than those in the control group(P<0.01). Before treatment, CRP, TNF-α, IL-6,IL-8,urinary inhibition level, cystatin C, IgA and IgM were not significant(P>0.05). After treatment, levels of CRP,TNF-α,IL-6 and IL-8,cystatin C,IgA and IgM were improved. Those of the observation group after treatment were better than those of the control group(P<0.05). There was one case of fatigue in the observation group(2.04%) and one case of headache in the control group(2.08%)(P>0.05). The 6-month recurrence rate in the observation group was 8.16%(4 cases),lower than 22.92%(11 cases) in the control group(P<0.05). Conclusion Huangqi Granule combined with sodium hydrocortisone succinate in the treatment of allergic purpura has a good clinical effect. It can improve the symptoms, accelerate the recovery, reduce the serum inflammatory factor level an

关 键 词：过敏性紫癜 黄芪颗粒 氢化可的松琥珀酸钠 疗效 不良反应 复发率 肾功能 

分 类 号：H259.546[语言文字—少数民族语言]